HomeNewsDrug Discovery & Development

Alkem Launches De Simone Formulation Probiotic DSS in India

Alkem Launches De Simone Formulation Probiotic DSS in India

Alkem Laboratories has introduced DSS, the original De Simone formulation probiotic blend, to the Indian market for restoring gut microbiota balance and managing a wide range of gastrointestinal conditions. Created by Professor Claudio De Simone, the formulation contains eight precisely selected bacterial strains designed to work synergistically on the gastrointestinal system.

Recognized globally as one of the most extensively studied probiotics, the De Simone formulation is supported by more than 80 clinical trials and 200 scientific publications. It is also recommended by leading gastroenterology associations in the USA and Europe for managing various gastrointestinal disorders. Alkem has in-licensed the formulation from Next Gen Pharma India Pvt. Ltd.

The DSS range will be available in four strengths—225 billion CFU sachet, 112.5 billion CFU capsule, 45 billion CFU capsule, and 10 billion CFU capsule—making Alkem the first company in India to offer all four strengths and to launch the 225 billion and 10 billion CFU variants with exclusive marketing rights.

This multi-strain probiotic blend includes four lactobacillus, three bifidobacterium, and one streptococcus strain, helping to restore microbial balance and deliver clinically proven benefits. DSS is indicated for conditions such as IBS, ulcerative colitis, pouchitis, hepatic encephalopathy, NAFLD, cirrhosis, bacterial vaginosis, antibiotic-associated diarrhoea, and other dysbiosis-related disorders. It is also suitable for use during pregnancy and lactation.

Alkem CEO Dr. Vikas Gupta said the launch aligns with rising awareness of gut health and strengthens the company’s gastrointestinal portfolio by offering a high-potency, evidence-backed probiotic solution.

Demand for probiotics in India continues to rise, with the prescription market valued at Rs. 2,071 crore and growing at a five-year CAGR of 14%, according to IQVIA (MAT October 2025).

Alkem Laboratories is one of India’s leading pharmaceutical companies and holds strong positions in anti-infectives, gastrointestinal medicines, pain management, and supplements.

More news about: drug discovery & development | Published by Darshana | November - 24 - 2025

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members